NEDD4L and Miyoshi myopathy: Clinical and molecular assessments revealed that increased expression of NEDD4L coincided with autophagy activation, which was correlated with a significantly elevated probability of responding to bortezomib, a prolonged response duration, and improved overall prognosis in MM patients (Huang et al. 2022).